Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem Cells and CNS Development

Lilian Wikström1, Alex Mercer

  • 1NeuroNova AB, Fiskartorpsvägen 15 A-D SE-114 33, Stockholm, Sweden

Drug Discovery Today
|November 9, 2001
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-analysis and Discussion of Appropriate Methodology.

Advances in therapy·2025
Same author

Authors' Reply: Questions Regarding the Analysis of Long-Term Outcomes in Nephrotic Syndrome.

Journal of the American Society of Nephrology : JASN·2025
Same author

Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria.

Journal of the American Society of Nephrology : JASN·2025
Same author

Long-term outcomes of patients with IgA nephropathy in the German CKD cohort.

Clinical kidney journal·2024
Same author

Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.

Clinical kidney journal·2024
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
Same journal

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026
Same journal

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
See all related articles